ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,20
-0,68%
S&P 500
5.306,04
0,02%
Dow Jones
38.852,86
-0,55%
Euro vs US Dollar
1,08506
-0,03%
Bitcoin
67.800,15
-0,72%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kura Oncology Inc (KURA)

  7. Kura Oncology Inc (KURA) News

KURA Kura Oncology Inc

21,49
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:00:00
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Kura Oncology Inc KURA NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 21,49 10:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
21,49
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
24.5.202422:06EDGAR2Form 8-K - Current report
21.5.202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.5.202422:19EDGAR2Form 144 - Report of proposed sale of securities
14.5.202413:30GLOBEKura Oncology Completes Enrollment in Registration-Directed..
08.5.202413:30GLOBEKura Oncology to Participate in Bank of America Securities..
03.5.202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
02.5.202422:05GLOBEKura Oncology Reports First Quarter 2024 Financial Results
25.4.202413:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
22.4.202413:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
10.4.202413:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
05.4.202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
06.3.202413:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
01.3.202423:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
27.2.202422:52EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202422:03EDGAR2Form 8-K - Current report
27.2.202422:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
26.2.202413:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
22.2.202413:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
20.2.202413:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
15.2.202422:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14.2.202423:58EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202423:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09.2.202423:21EDGAR2Form S-3 - Registration statement under Securities Act of..
02.2.202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
31.1.202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202422:10EDGAR2Form 144 - Report of proposed sale of securities
30.1.202413:08EDGAR2Form 8-K - Current report
30.1.202413:00GLOBEKura Oncology Reports Positive Preliminary Ziftomenib..
26.1.202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.1.202422:08EDGAR2Form 8-K - Current report
24.1.202422:12EDGAR2Form 144 - Report of proposed sale of securities
24.1.202413:00GLOBEKura Oncology Announces Oversubscribed $150 Million Private..
04.1.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202315:01EDGAR2Form 8-K - Current report
11.12.202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.12.202313:30GLOBEKura Oncology’s Menin Inhibitor Ziftomenib Selected for The..
28.11.202313:30GLOBEKura Oncology to Participate in the JMP Securities..
02.11.202321:39EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02.11.202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202321:03EDGAR2Form 8-K - Current report
02.11.202321:01GLOBEKura Oncology Reports Third Quarter 2023 Financial Results
02.11.202312:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..

Kürzlich von Ihnen besucht

NASDAQ
KURA
Kura Oncology
LSE
AS71
Comw.bk.a.24
NASDAQ
CFMSX
Column Mid Cap Select
BIT
S27196
Societe Generale Effekten
COIN
ZENUST
Horizen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten